|
Journal characteristics
|
|
Journal Impact factor
|
| Range 0.34–44.02 |
45/56 (80) |
0.794 (0.619, 0.967) |
0.0109 |
| Mean Value = 4.63 |
|
|
|
| Std deviation = 6.06 |
|
|
|
| Median Value = 2.84 |
|
|
|
|
Study characteristics
|
|
Comparison Groups
|
| Placebo Controlled trial |
25/28 (89) |
1.00 |
|
| Drug–drug Comparative trial |
23/33 (70) |
0.276 (0.044, 1.277) |
0.1178 |
|
Sample size
|
|
|
|
| Range 20–4360 |
48/61 (79) |
1.000 (0.999, 1.001) |
0.4099 |
| Mean Value = 390 |
|
|
|
| Std deviation = 590.4 |
|
|
|
| Median Value = 252 |
|
|
|
|
Study design characteristics aimed at reducing bias
|
|
Randomization/Concealment of allocation
|
|
|
|
| Adequate |
13/15 (87) |
2.043 (0.362, 21.213) |
0.6354 |
|
Blinding
|
|
|
|
| Adequate |
31/36 (86) |
2.918 (0.698, 13.026) |
0.1689 |
|
ITT Analysis
|
|
|
|
| Adequate |
39/48 (81) |
1.445 (0.208, 7.501) |
0.8959 |
|
Follow-up
|
|
|
|
| Adequate |
38/49 (78) |
0.691 (0.065, 4.051) |
1.0000 |
|
Appropriate Medication Dosing
|
|
|
|
| Test drug – Adequate |
48/60 (80) |
Infinite (0.095, Infinite) |
0.4262 |
| Comparator drug - Adequate |
20/30 (67) |
0 (0, 5.654) |
0.6492 |
|
Author characteristics
|
|
Corresponding Author Institutional Affiliation
|
|
|
|
| Test drug company |
15/16 (94) |
Infinite (0.192, Infinite) |
0.2353 |
| Any other industry |
0/1 (0) |
– |
– |
| Academic/Hospital |
33/43 (77) |
Infinite (0.077, Infinite) |
0.5000 |
| All Other |
0/1 (0) |
1.000 |
– |
|
Funding information
|
|
Funding source
|
|
|
|
| Test drug company/any other industry/other drug companies |
1/2 (50) |
0.130 (0.002, 13.627) |
0.5397 |
| Test drug company employee author/no formal disclosure |
2/2 (100) |
Infinite (0.020, Infinite) |
1.0000 |
| Any other drug company |
1/6 ((17) |
0.026 (0, 0.400) |
0.0030 |
| No drug company |
1/1 (100) |
Infinite (0.003, Infinite) |
1.0000 |
| No funding disclosure |
20/24 (83) |
0.652 (0.086, 4.407) |
0.9068 |
|
Test drug funding
|
|
|
|
| Test drug funding |
26/30 (87) |
2.659 (0.623, 13.280) |
0.2357 |
|
Corresponding Author Financial Ties
|
|
|
|
| Test drug company ties/any other industry ties |
2/5 (40) |
0 (0, 1.644) |
0.1212 |
| Test drug company employee/no formal disclosure of ties |
15/15 (100) |
1.000 |
– |
| Any other industry ties |
1/2 (50) |
0 (0, 13.000) |
0.5000 |
| No disclosure of ties |
23/32 (72) |
0 (0, 2.705) |
0.3441 |
|
Corresponding Author Test Drug Financial Ties
|
| Test drug financial ties |
23/26 (89) |
3.067 (0.664, 19.156) |
0.1937 |
|
First Author Financial Ties
|
|
|
|
| Test drug company ties/any other industry ties |
2/5 (40) |
0 (0, 2.027) |
0.1667 |
| Test drug company employee/no formal disclosure of ties |
5/5 (100) |
1.000 |
– |
| Any other industry ties |
1/2 (50) |
0 (0, 15.600) |
0.5714 |
| No disclosure of ties |
35/44 (80) |
0 (0, 5.075) |
0.6901 |
|
First Author Test Drug Financial Ties
|
| Test drug financial ties |
12/15 (80) |
1.111 (0.230, 7.302) |
1.0000 |
